Za
Non verificato

Zai Lab Limited

Di cosa scriviamo

BiotecnologiaFarmaceuticaOncologiaSaluteScienza
09/06/2026
Industria
Oncologia
Salute
Sanità
Medicina nucleare
Medicina - Varie
Farmaceutica
Biotecnologia
Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer
1.00
21/05/2026
Mercato del lavoro
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Farmaceutica
Biotecnologia
Zai Lab Announces Changes to Senior Leadership Team
1.00
11/05/2026
Eventi
Industria
Igiene alimentare
Medicina - Varie
Biotecnologia
Medicina nucleare
Salute
Farmaceutica
Sanità
Oncologia
Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)
1.00
07/05/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Farmaceutica
Biotecnologia
Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates
1.00
22/04/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026
1.00
17/04/2026
Eventi
Industria
Web e Social Network
Telefonia e Varie
Igiene alimentare
Medicina - Varie
Biotecnologia
Medicina nucleare
Salute
Farmaceutica
Sanità
Oncologia
Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas
1.00
01/04/2026
Mercato del lavoro
Industria
Oncologia
Salute
Medicina - Varie
Medicina nucleare
Farmaceutica
Biotecnologia
Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy
1.00
26/02/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Farmaceutica
Biotecnologia
Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
1.00

Recapiti

Social Media

Seguaci
0
Compatibilità
0